-

Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:

Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 10th, 2024 to present the half-year financial results (April 2024-September 2024)

> Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/

> Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/

Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference.

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals

medincell.com

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Medincell

BOURSE:MEDCL
Release Versions
EnglishFrench

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell Publishes its Consolidated Half-Year Financial Results

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): “We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading...

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population2 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia2 Teva press release: https://ir.tevapharm.com/news-and-events/press-re...

Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025) > Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/ > Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/ Shareholders are invited to send their questions to communication@medincell.com, or through the chat system during the videoconference. About...
Back to Newsroom